Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494024 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
A Phase 1 study, sponsored by C2N Diagnostics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02494024 is a Phase 1 study that has completed, run by C2N Diagnostics. The registered enrollment target is 32 participants.
The verdict
NCT02494024, a Phase 1 study, has completed, sponsored by C2N Diagnostics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
Interventions
- DRUG Single dose placebo
- DRUG Single dose C2N-8E12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494024
The ClinicalTrials.gov registry entry for NCT02494024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C2N Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Single dose placebo is the first listed.
NCT02494024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494024 about?
NCT02494024 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy". This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
What is the current status of trial NCT02494024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02494024?
The interventions under investigation include: Single dose placebo (DRUG), Single dose C2N-8E12 (DRUG).
Who is sponsoring clinical trial NCT02494024?
This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.